NCT04692155 2023-09-28
CHOP U2
University of Alabama at Birmingham
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT02867618 2021-07-16
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Columbia University
Phase 1/2 Terminated